Cite
MLA Citation
Thomas Powles et al.. “Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC).” Journal for immunotherapy of cancer, vol. 3, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100137782851.0x000002